Cargando…
Botulinum toxin and benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH) is a clinical condition where lower urinary tract symptoms are caused by both a physically obstructing prostate as well as tight smooth muscles around the bladder outlet. Treatment of this condition with botulinum toxin has been used since 2003, but this interest h...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Second Military Medical University
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5780293/ https://www.ncbi.nlm.nih.gov/pubmed/29379734 http://dx.doi.org/10.1016/j.ajur.2017.11.003 |
_version_ | 1783294706146344960 |
---|---|
author | Ng, Lay Guat |
author_facet | Ng, Lay Guat |
author_sort | Ng, Lay Guat |
collection | PubMed |
description | Benign prostatic hyperplasia (BPH) is a clinical condition where lower urinary tract symptoms are caused by both a physically obstructing prostate as well as tight smooth muscles around the bladder outlet. Treatment of this condition with botulinum toxin has been used since 2003, but this interest has somewhat died down after two large randomized controlled trials (RCTs) showing equivalence of results between their treatment and placebo arms. However, with review of animal studies and unexplained exaggerated effect of the placebo arms of the two RCTs, together with recent data of sustained benefits after 18 months of treatment, the place of botulinum toxin in the BPH field is probably still present. |
format | Online Article Text |
id | pubmed-5780293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Second Military Medical University |
record_format | MEDLINE/PubMed |
spelling | pubmed-57802932018-01-29 Botulinum toxin and benign prostatic hyperplasia Ng, Lay Guat Asian J Urol Review Benign prostatic hyperplasia (BPH) is a clinical condition where lower urinary tract symptoms are caused by both a physically obstructing prostate as well as tight smooth muscles around the bladder outlet. Treatment of this condition with botulinum toxin has been used since 2003, but this interest has somewhat died down after two large randomized controlled trials (RCTs) showing equivalence of results between their treatment and placebo arms. However, with review of animal studies and unexplained exaggerated effect of the placebo arms of the two RCTs, together with recent data of sustained benefits after 18 months of treatment, the place of botulinum toxin in the BPH field is probably still present. Second Military Medical University 2018-01 2017-11-22 /pmc/articles/PMC5780293/ /pubmed/29379734 http://dx.doi.org/10.1016/j.ajur.2017.11.003 Text en © 2018 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Ng, Lay Guat Botulinum toxin and benign prostatic hyperplasia |
title | Botulinum toxin and benign prostatic hyperplasia |
title_full | Botulinum toxin and benign prostatic hyperplasia |
title_fullStr | Botulinum toxin and benign prostatic hyperplasia |
title_full_unstemmed | Botulinum toxin and benign prostatic hyperplasia |
title_short | Botulinum toxin and benign prostatic hyperplasia |
title_sort | botulinum toxin and benign prostatic hyperplasia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5780293/ https://www.ncbi.nlm.nih.gov/pubmed/29379734 http://dx.doi.org/10.1016/j.ajur.2017.11.003 |
work_keys_str_mv | AT nglayguat botulinumtoxinandbenignprostatichyperplasia |